MedMira Wins Government Tender for Rapid HIV Test in China MiraWell(R) Rapid HIV Test Selected Based on Quality and Performance HALIFAX, March 7 /PRNewswire-FirstCall/ -- MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ:MMIRF) the global market leader in rapid flow-through diagnostic technology, announced today that it has won the first rapid HIV test tender in the province of Jilin in the People's Republic of China. The tender is structured as an annual standing order through which all levels of provincial public health organizations in Jilin will be able to order MedMira's MiraWell(R) Rapid HIV Test. The first shipment against this standing order is expected within the next 30 days and is estimated to be for approximately 100,000 tests. "We are very excited about this achievement, and would like to congratulate our sales and marketing team as well as our distributor in Jilin province," said Stephen Sham, chairman and chief executive officer of MedMira. "Although we anticipated our success in winning this public tender, as part of the next step in our China marketing plan, this accomplishment has reassured us of the China government's commitment to control HIV by using only the highest quality and best performing rapid HIV test in the front lines of public health." According to the Chinese National CDC 2004 evaluation report, MedMira's MiraWell(R) Rapid HIV Test performed the best of the ten rapid HIV tests evaluated, and was found to be as accurate as traditional testing methods. Sham continued, "We anticipate that the demand for our rapid HIV test will reach new levels in 2005 as the China government continues its battle to reduce HIV transmission within its population of approximately 1.3 billion. We expect that many more China provinces will offer similar public tenders and we are confident that MedMira's proven rapid HIV test will lead this market." China has been reported to be battling one of the most rapidly increasing HIV-infection rates in the world (rising 30% yearly since 1998). It is currently estimated that 1 million Chinese are HIV-infected and that, without intervention, China can anticipate this to increase to 10 million by 2010. About Jilin Province, P.R. China Home to 26 million people, Jilin is the most urbanized province in China. The provincial capital, Changchun, is remembered in history as the capital of Manchukuo - "land of the Manchus" - the puppet state established by the Japanese in 1932 after invading Manchuria in September 1931. To add legitimacy to their conquest, the Japanese named Puyi, the last Qing (Ch'ing) emperor, as Manchukuo's ruler. Following World War II, Puyi was "re-educated" by the Communists and spent the rest of his life working at Beijing's botanical garden. Changchun is a major food-processing center that serves the agriculturally rich Songhua River valley. About MedMira MedMira is the leading global manufacturer and marketer of in vitro flow- though rapid diagnostic tests for the clinical laboratory market. MedMira's tests provide reliable, rapid diagnosis in just 3 minutes for the detection of human antibodies in human serum, plasma or whole blood for diseases such as HIV. The United States FDA and the SFDA in the People's Republic of China have approved MedMira's Reveal(R) G2 and MiraWell(R) Rapid HIV Tests, respectively. For more information visit MedMira's website at http://www.medmira.com/. MedMira's Reveal(R) G2 and MiraWell(R) rapid HIV tests are currently used in clinical laboratories and hospitals where professional counseling and patient treatment are immediately available. The MiraCare(TM) Rapid HIV Antibody Test is available over-the-counter (OTC) in pharmacies throughout the Hong Kong and Macao Special Administrative Regions, in P.R. China. MedMira markets its rapid tests worldwide in such countries as the United States, Canada, South Africa and China. Its corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada with a representative office in Beijing, China. This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement. DATASOURCE: MedMira Inc. CONTACT: Media Contact: Investor Relations, Dr. James Smith: (902) 450-1588 or e-mail:

Copyright